Background: Methylphenidate-based designer drugs are new psychoactive substances (NPS) that are used outside medical settings and their pharmacology is largely unexplored. We also investigated monoamine efflux and monoamine receptor and transporter binding affinities. Furthermore, we assessed the cell integrity under assay conditions.
Introduction
The psychostimulant methylphenidate (MPH; Ritalin ® ) is used for the treatment of attention-deficit/hyperactivity disorder and narcolepsy but it also has a history of being misused as a 'smart drug' and 'cognitive enhancer' (Arria et al., 2008; Liakoni et al., 2015; Maier et al., 2013) . In recent years, an increasing number of MPH-based new psychoactive substances (NPS; Fig. 1 ) (Brandt et al., 2014) have become available as alternatives to MPH (Bailey et al., 2015 ; European Monitoring Centre for Drugs and Drug Addiction, 2015) and have been associated with several fatalities (Krueger et al., 2014; Maskell et al., 2016; Parks et al., 2015) . Characteristic for the NPS phenomenon, many of the currently circulating MPH analogs originated from drug development efforts (Deutsch et al., 1996; Markowitz et al., 2013; Misra et al., 2010) , which subsequently appeared on the streets. The pharmacological and subjective-effect profiles of MPH are very similar to cocaine (Simmler et al., 2014; Vogel et al., 2016; Volkow et al., 1999) . Furthermore, some of these substances are either sold in their own right or offered in the form of branded products (Bailey et al., 2015; Parks et al., 2015) . Methylphenidate predominantly inhibits the norepinephrine (NE) and dopamine (DA) transporters (NET and DAT, respectively), thus, possibly contributing to its abuse 4 potential (Simmler et al., 2014; Vogel et al., 2016) . Correspondingly, questions arise about the extent to which MPH analogs might share MPH-like characteristics. Assessing the pharmacological profile of NPS in vitro is an initial step to gain a better understanding of the potential clinical effects and toxicology of these substances. For this reason, the present study reports on the transporter interaction profiles of the MPH-related NPS Nbenzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, and isopropylphenidate and the transporter and receptor interaction profiles of ethylnaphthidate, ethylphenidate, 4-fluoromethylphenidate, 4-methylmethylphenidate, methylmorphenate, and
propylphenidate. Modafinil, a stimulant prescribed for the treatment of narcolepsy, which is frequently offered for sale as a 'neuroenhancer' (Ghahremani et al., 2011; Maier et al., 2013; Mereu et al., 2013; Müller et al., 2013) , has also been included in this investigation.
Stimulants may act as transporter inhibitors or as transporter substrates that cause monoamine efflux into the synaptic cleft (Rothman and Baumann, 2003; Sitte and Freissmuth, 2015) .
Therefore, additionally to the transporter inhibition potencies of the substances, their mechanism of action (reuptake inhibitor or transporter substrate) was determined.
Material and methods

Drugs
Cocaine, 3,4-methylenedioxymethamphetamine (MDMA) and MPH were purchased from Lipomed (Arlesheim, Switzerland), with high-performance liquid chromatography (HPLC) purity > 98.5%. Modafinil was purchased from Cayman Chemicals (Ann Arbor, MI, USA), with purity > 98%. Methylmorphenate and propylphenidate were obtained from reChem Labs (Ontario, Canada) and afterwards identified and tested for purity using nuclear magnetic resonance (NMR) and HPLC, which revealed purity > 95%. N- (Klare et al., 2017) . The substances were fully characterized in a previous study (Klare et al., 2017) and purity values were estimated at > 95% based on spectroscopic and 
Monoamine uptake transport inhibition
Monoamine uptake inhibition was assessed using human embryonic kidney (HEK) 293 cells that stably expressed the human SERT, DAT, or NET (Tatsumi et al., 1997) as previously described (Hysek et al., 2012) . Briefly, the cells were cultured to 70-90% confluence, detached, and resuspended in Krebs-Ringer Bicarbonate Buffer (Sigma-Aldrich, Buchs, Switzerland). For [ 3 H]-DA uptake experiments, the uptake buffer was supplemented with 1.14 mM ascorbic acid. The cells were then treated with vehicle control and drug in the range of 1 nM to 900 µM for 10 min at room temperature. Additionally, monoamine-specific inhibitors were added (10 µM fluoxetine for SERT, 10 µM mazindol for DAT, and 10 µM nisoxetine for NET 
Transporter-mediated monoamine efflux
The potential of the drugs to initiate transporter-mediated NE, DA, or 5-HT efflux was assessed in HEK 293 cells that overexpressed the respective transporter as previously described (Simmler et al., 2013 were added as a negative control at a concentration of 10 µM to determine "pseudo-efflux" that was caused by nonspecific monoamine efflux and subsequent reuptake inhibition (Scholze et al., 2000) .
Radioligand receptor and transporter binding assays
The radioligand binding assays were performed as previously described for transporters (Hysek et al., 2012) and receptors (Revel et al., 2011) . Briefly, membrane preparations of HEK 293 cells (Invitrogen, Zug, Switzerland) that overexpressed the respective transporters (Tatsumi et al., 1997) or receptors (human genes, with the exception of rat and mouse genes for trace amine-associated receptors [TAARs]) (Revel et al., 2011) 
Activity at the serotonin 5-HT 2B receptor
Activity at the 5-HT 2B receptor was assessed as previously described (Rickli et al., 2016) . Briefly, human 5-HT 2B receptor-expressing HEK 293 cells were incubated in a cell culture plate overnight. The next day, the growth medium was removed by snap inversion, and calcium indicator Fluo-4 solution (Molecular Probes, Eugene, OR, USA) was added to each well. The plates were then incubated for 45 min at 31ºC. The Fluo-4 solution was removed by snap inversion and then added a second time. The cells were then incubated for another 45 min at 31ºC. Immediately before testing, the cells were washed with HBSS and 20 mM HEPES (assay buffer; Gibco) using an EMBLA cell washer, and assay buffer was added. The plates were placed in a FLIPR. Test substances that were diluted in assay buffer were added online, and the increase in fluorescence was measured.
Cytotoxicity 8
Cytotoxicity was assessed with the ToxiLight bioassay kit (Lonza, Basel, Switzerland) according to the manufacturer's protocol. The kit measures adenylate kinase release as a result of cell membrane integrity loss. Human SERT-, DAT-, and NETtransfected HEK 293 cells were treated for 1 h at room temperature with the drugs at the highest assay concentrations.
Statistical analysis
Calculations were performed using Prism 7.0a software (GraphPad, San Diego, CA, USA). Monoamine transporter inhibition data were fit by nonlinear regression to variableslope sigmoidal dose-response curves and IC 50 values were assessed. The DAT/SERT ratio is expressed as 1/DAT IC 50 :1/SERT IC 50 . Compound-induced monoamine efflux of five independent experiments was compared with negative controls using analysis of variance followed by the Holm-Sidak test. P values lower than 0.05 were considered significant and substances were considered transporter substrates if they caused significantly higher efflux than the negative controls. IC 50 values of radioligand binding were determined by calculating nonlinear regression curves for a one-site model using three independent 10-point concentration-response curves for each compound. K i (affinity) values, which correspond to the dissociation constants, were determined using the Cheng-Prusoff equation. Nonlinear regression concentration-response curves were used to calculate the EC 50 values for the 5-HT 2B receptor activation.
Results
Monoamine uptake transporter inhibition
Monoamine uptake inhibition curves are shown in Fig. 2 , and the corresponding IC 50 values and DAT/SERT inhibition ratios are listed in Table 1 . Methylphenidate was a potent 9 inhibitor of the NET and DAT at submicromolar concentrations and a weak inhibitor of the SERT. 3,4-dichloromethylphenidate inhibited the NET more than 10-fold more potently than MPH, whereas the inhibition potency for the DAT was more than 2-fold increased. 
Monoamine efflux
Similar to cocaine, MPH and the MPH-based NPS and related compounds did not cause monoamine efflux (Fig. 3) and are therefore not transporter substrates.
Monoamine receptor and transporter binding affinities
The interactions between MPH-based NPS and related compounds with monoamine receptors and transporters are shown in Modafinil and cocaine bound to the monoamine transporters but did not interact with monoamine or trace amine receptors.
Cytotoxicity
Cytotoxicity was not observed for any of the drugs in the functional assays at the concentrations tested, thus confirming cell integrity during the assays.
Discussion
We characterized the in vitro pharmacological profiles of MPH-based NPS and compared them with MPH and cocaine. All compounds inhibited the DAT substantially more potently than the SERT, suggesting predominantly stimulant-type effects similar to amphetamine and a high abuse liability (Liechti, 2015; Simmler et al., 2013) . 
Monoamine uptake transporter inhibition and monoamine efflux
Methylphenidate and MPH-based NPS, with the exception of Nbenzylethylphenidate, isopropylphenidate, and methylmorphenate, inhibited the NET at submicromolar concentrations, suggesting cardiostimulant and psychostimulant properties, similar to amphetamines (Hysek et al., 2011; Simmler et al., 2013) . Moreover, the NET and DAT inhibition potencies but not the SERT inhibition potency correlate with the psychotropic effective doses of psychostimulants in human (Simmler et al., 2013) .
The MPH-based NPS were only monoamine transporter inhibitors and not monoamine transporter substrates, indicating a mechanism of action similar to cocaine but not amphetamines (Fleckenstein et al., 2007; Torres et al., 2003) . Ethylnaphthidate inhibited the SERT at low micromolar concentrations, but the remaining MPH-based NPS displayed a clear preference for DAT over SERT, resulting in high DAT/SERT ratios frequently reported for locomotor stimulants (Simmler et al., 2013) . Our results are consistent with other studies that reported potent NET and DAT inhibition for MPH (DAT/SERT ratio = 2207) and triple uptake inhibition for cocaine (DAT/SERT ratio = 3.2) (Han and Gu, 2006) . Modafinil was a moderate and relatively selective DAT inhibitor, with an IC 50 value of 11 µM. This finding is consistent with previous in vitro studies that reported IC 50 values of 4-13 µM (Karabacak et al., 2015; Loland et al., 2012; Madras et al., 2006; Zolkowska et al., 2009 ). The interaction between modafinil and DAT is also thought to modulate the pharmacological effects of the drug (Wisor, 2013) . The psychopharmacological profiles and cognitive-enhancing properties of MPH and modafinil may be different. Modafinil has been shown to improve attention and wakefulness, whereas MPH has been shown to improve memory (Repantis et al., 2010) . indicating that they exert their primary effects by inhibiting uptake transporters, similar to MPH and cocaine (Ritz et al., 1987 (Ritz et al., , 1988 Volkow et al., 2002) . Consistent with the monoamine uptake data, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, and ethylnaphthidate potently bound to the NET and DAT and had affinity for the SERT as well.
Transporter and receptor binding profiles
4-Fluoromethylphenidate, 4-methylmethylphenidate, and methylphenidate bound potently to the NET and DAT but had no affinity to the SERT in the tested concentration range. NBenzylethylphenidate, ethylphenidate, isopropylphenidate, and propylphenidate showed high affinity for the DAT but not for the NET or SERT. Methylmorphenate did not potently bind to any transporter. Cocaine potently bound to all transporters but not to receptors. No interaction between modafinil and monoamine receptors was observed. To date, no single site of action for modafinil has been identified (Gerrard and Malcolm, 2007) .
Comparison of transporter binding and transporter inhibition
No drug-mediated monoamine efflux was observed for any of the MPH-based compounds, strengthening the argument that they are pure uptake blockers.
For uptake blockers, a correlation between the monoamine uptake and radioligand binding affinities has been previously described for the NET (Cheetham et al., 1996; Lee et al., 1982) , the DAT (Javitch et al., 1984; Schoemaker et al., 1985) , and the SERT (D' Amato et al., 1987; Langer et al., 1980) . However, discrepancies between monoamine uptake inhibition and 13 radioligand binding have been observed for cocaine-like drugs and proposed for MPH-like drugs, when the conditions for the binding and uptake inhibition assays varied (Reith et al., 2005; Rothman et al., 1993) .
Highest NET and DAT binding affinities were observed for the most potent NET and DAT inhibitor 3,4-dichloromethylphenidate. However, the increase in potency compared to MPH was much more pronounced with a 76-fold and 12-fold increase for NET and DAT binding, respectively. 3,4-Dichloroethylphenidate bound more than 10-fold more potently to the NET and DAT whereas the NE and DA uptake inhibition was similar to MPH.
Ethylnaphthidate, 4-fluoromethylphenidate, and 4-methylmethylphenidate inhibited the NET and DAT with similar potency as MPH. These substances bound to the NET with affinity in the range of 0.22-0.31 µM and to the DAT with affinity in the range of 0.026-0.040 µM.
MPH bound to the NET and DAT with 0.50 µM and 0.070 µM, respectively. Thus, as observed for the NET and DAT, the SERT binding affinity of Nbenzylethylphenidate was much higher than might be expected from the uptake inhibition data.
To conclude, the rank order of potency of the radioligand binding and uptake inhibition was similar with the 3,4-substituted and 4-substitued compounds being among the most potent MPH-based NPS; the relative potencies of the uptake inhibition and transporter binding varied however to a certain extent. The present study has limitations. Possible potent contaminants could theoretically have influenced the results for some drugs with lower purity. Substance-induced efflux was only tested at a high substance concentration. The absence of monoamine efflux could be the result of bell-shaped concentration-efflux curves as it has been demonstrated for amphetamine analogs with known monoamine releasing properties, including MDMA, in different in vitro assays (Seidel et al., 2005) . However, such bell-shaped efflux curves were not observed in the assay used in the present study as previously documented (Hysek et al., 2012) , strengthening the argument that the MPH-based NPS are in fact pure uptake inhibitors. Moreover, in this study the focus was laid on the NET, DAT, and SERT, as they are main targets of amphetamines and presumably many stimulant NPS (Sitte and Freissmuth, 2015) . Other possible mechanisms that may contribute to the effects of NPS, 15 such as VMAT2 inhibition (Sulzer et al., 2005) , calcium-triggered exocytosis of monoamines (Mundorf et al., 1999; Sulzer et al., 2005) , mRNA regulation (Douglass et al., 1995) , or ion channel blockage (Bauman and DiDomenico, 2002; O'Leary and Hancox, 2010) , were not investigated in this study.
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